Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential C-H Arylation and Enantioselective Hydrogenation Enables Ideal Asymmetric Entry to the Indenopiperidine Core of an 11β-HSD-1 Inhibitor.
Wei X, Qu B, Zeng X, Savoie J, Fandrick KR, Desrosiers JN, Tcyrulnikov S, Marsini MA, Buono FG, Li Z, Yang BS, Tang W, Haddad N, Gutierrez O, Wang J, Lee H, Ma S, Campbell S, Lorenz JC, Eckhardt M, Himmelsbach F, Peters S, Patel ND, Tan Z, Yee NK, Song JJ, Roschangar F, Kozlowski MC, Senanayake CH. Wei X, et al. Among authors: peters s. J Am Chem Soc. 2016 Nov 30;138(47):15473-15481. doi: 10.1021/jacs.6b09764. Epub 2016 Nov 17. J Am Chem Soc. 2016. PMID: 27794616 Free PMC article.
BILN: A Human-Readable Line Notation for Complex Peptides.
Fox T, Bieler M, Haebel P, Ochoa R, Peters S, Weber A. Fox T, et al. Among authors: peters s. J Chem Inf Model. 2022 Sep 12;62(17):3942-3947. doi: 10.1021/acs.jcim.2c00703. Epub 2022 Aug 19. J Chem Inf Model. 2022. PMID: 35984937
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science.
Thamm S, Willwacher MK, Aspnes GE, Bretschneider T, Brown NF, Buschbom-Helmke S, Fox T, Gargano EM, Grabowski D, Hoenke C, Matera D, Mueck K, Peters S, Reindl S, Riether D, Schmid M, Tautermann CS, Teitelbaum AM, Trünkle C, Veser T, Winter M, Wortmann L. Thamm S, et al. Among authors: peters s. J Med Chem. 2023 Feb 23;66(4):2832-2850. doi: 10.1021/acs.jmedchem.2c01884. Epub 2023 Feb 2. J Med Chem. 2023. PMID: 36727857 Free PMC article.
Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses.
Laurie S, Steyaert W, de Boer E, Polavarapu K, Schuermans N, Sommer AK, Demidov G, Ellwanger K, Paramonov I, Thomas C, Aretz S, Baets J, Benetti E, Bullich G, Chinnery PF, Clayton-Smith J, Cohen E, Danis D, de Sainte Agathe JM, Denommé-Pichon AS, Diaz-Manera J, Efthymiou S, Faivre L, Fernandez-Callejo M, Freeberg M, Garcia-Pelaez J, Guillot-Noel L, Haack TB, Hanna M, Hengel H, Horvath R, Houlden H, Jackson A, Johansson L, Johari M, Kamsteeg EJ, Kellner M, Kleefstra T, Lacombe D, Lochmüller H, López-Martín E, Macaya A, Marcé-Grau A, Maver A, Morsy H, Muntoni F, Musacchia F, Nelson I, Nigro V, Olimpio C, Oliveira C, Paulasová Schwabová J, Pauly MG, Peterlin B, Peters S, Pfundt R, Piluso G, Piscia D, Posada M, Reich S, Renieri A, Ryba L, Šablauskas K, Savarese M, Schöls L, Schütz L, Steinke-Lange V, Stevanin G, Straub V, Sturm M, Swertz MA, Tartaglia M, Te Paske IBAW, Thompson R, Torella A, Trainor C, Udd B, Van de Vondel L, van de Warrenburg B, van Reeuwijk J, Vandrovcova J, Vitobello A, Vos J, Vyhnálková E, Wijngaard R, Wilke C, William D, Xu J, Yaldiz B, Zalatnai L, Zurek B; Solve-RD DITF-GENTURIS; Solve-RD DITF-ITHACA; Solve-RD DITF-EURO-NMD; Solve-RD DITF-RND; Solve-RD co… See abstract for full author list ➔ Laurie S, et al. Among authors: peters s. Nat Med. 2025 Jan 17. doi: 10.1038/s41591-024-03420-w. Online ahead of print. Nat Med. 2025. PMID: 39825153
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial.
Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, Shah R, de Marinis F, Cove Smith L, Bernabé R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Nadal E, Vila Martinez L, Talbot T, Roschitzki-Voser H, Dimopoulou G, Schär S, Ruepp B, Savic S, Peters S, Stahel R. Felip E, et al. Among authors: peters s. Ann Oncol. 2025 Jan 13:S0923-7534(25)00003-1. doi: 10.1016/j.annonc.2024.12.014. Online ahead of print. Ann Oncol. 2025. PMID: 39814199
Severity of Impaired Oxygenation and Conservative Oxygenation Targets in Mechanically Ventilated Children: A Post Hoc Subgroup Analysis of the Oxy-PICU Trial of Conservative Oxygenation.
Ray S, Wiegand M, Gould DW, Harrison DA, Mouncey PR, Peters MJ; Oxy-PICU Investigators of the United Kingdom Paediatric Critical Care Society Study Group. Ray S, et al. Pediatr Crit Care Med. 2025 Jan 13. doi: 10.1097/PCC.0000000000003686. Online ahead of print. Pediatr Crit Care Med. 2025. PMID: 39803991
3,763 results